RGC-32 as a potential marker of relapse and response to treatment with glatiramer acetate in multiple sclerosis

Authors :: Christopher T. Bever
Walter Royal
Violeta Rus
Adam M. Kruszewski
Vingh Nguyen
Cornelia Cudrici
Horea Rus
Source :: Journal of the Neurological Sciences. 357:e17
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
medicine.medical_specialty
Neurology
business.industry
Multiple sclerosis
Internal medicine
medicine
Neurology (clinical)
Glatiramer acetate
medicine.disease
business
Response to treatment
medicine.drug

Full Text Access

Tools